HFpEF Phenotyping With Echo, Clinical, and Biomarkers
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Of Perugia
About this trial
The EPIC-HFpEF registry is a nationwide Italian study that follows people with a specific type of heart failure called HFpEF. About 500 patients will be enrolled from several specialized hospitals and monitored for up to two years, without changing their usual treatment.
The goal is to better understand this complex condition by identifying different patient "types" based on clinical features, heart imaging, and blood markers. Researchers will also look at how these groups are treated in real life and how their disease progresses over time.
By doing this, the study aims to improve how doctors classify and manage HFpEF, moving toward more personalized and effective care for patients in the future.
Eligibility criteria
Qualifiers
Patients ≥ 18 years old
Signed patient informed consent form (ICF)
Diagnosis of chronic (documented HF hospitalization in the last year) or acute decompensated HF shown by signs and symptoms of HF and LVEF >50% and, according to guidelines and the universal definition of HF, elevated levels of natriuretic peptides (NT-proBNP ≥300 pg/ml in sinus rhythm or NTproBNP ≥600 pg/ml in atrial fibrillation), at the time of enrolment (10)
Echocardiographic evidence of increased estimated LV filling pressures according to current guidelines
Disqualifiers
Planned participation or participation in a clinical trial;
Life expectancy < 1 year because of non-cardiac causes;
History of recent (6 months) infective, or inflammatory, autoimmune or neoplastic diseases.
Stage >4 CKD (estimated glomerular filtration rate [eGFR] < 15 ml/min/1.73m2),
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
University Of Perugia
Lead sponsor
Azienda Ospedaliera di Perugia
Collaborator
Ospedale Le Scotte
Collaborator
University of Foggia
Collaborator
Source ClinicalTrials.gov